AKT1 and cancer: In summary, the selective cytotoxicity of VCP inhibition towards cancer cells can be attributed to the disruption of proteotoxic stress mitigation pathways involving the ATF4/DDIT4 axis and hyperactive mTORC2/Akt signaling.